Skip to main content

Acute lymphoblastic leukemia (ALL) diagnosis

Diagnosing acute lymphoblastic leukemia (ALL) and your ALL subtype usually involves a series of tests. An accurate diagnosis of your subtype is important. The exact diagnosis helps your doctor estimate how the disease will progress and determine the appropriate treatment.

The information on this page covers how ALL is diagnosed in adults. Visit Childhood ALL to learn about signs and symptoms, diagnosis, and treatment information for children with ALL. 

Tests your doctor may use to diagnose ALL

Your doctor may use the following tests to diagnosed ALL:

Blood and bone marrow tests 

Blood tests measure the number of red and white blood cells and platelets in the blood; bone marrow tests measure the fluid and tissue in your marrow. Open each section below to learn more.

This test is used to measure the number of red blood cells, white blood cells, and platelets in a sample of blood. It measures the amount of hemoglobin in the red blood cells. The CBC should include a differential, which measures the numbers of the different types of white blood cells in the sample. People with ALL often have lower-than-normal numbers of red blood cells and platelets and may have higher-than-normal or lower-than-normal white blood cell counts. 

If the CBC findings suggest leukemia, a diagnosis of ALL can sometimes be confirmed with additional testing of the blood sample. Sometimes, however, an ALL diagnosis can be made only after the examination of a sample of bone marrow cells. 

These two procedures are generally done at the same time in a doctor's office or a hospital. For both procedures, the patient is given general anesthesia or medication to numb the area. The samples are usually taken from the hip bone using special needles.  

  • A bone marrow aspiration removes a liquid marrow sample
  • A bone marrow biopsy removes a small amount of bone filled with marrow 

Learn more about bone marrow tests.

View the interactive 3D model to help you visualize and better understand the procedure. Click or tap the "Interact in 3D" button to begin. 

Biomarker testing 

These laboratory tests check for changes in the proteins, genes, and chromosomes of the cancer cells. Each person's cancer has a unique pattern of biomarkers. Biomarker testing is used to help determine the subtype of ALL and plan treatment. Open each section below to learn more.

This test is used to identify cells based on the types of proteins on the cell surfaces. It can help determine whether a person has B-cell ALL or T-cell ALL and the subtype of ALL. This test can also be used to see if there are any residual cancer cells remaining in the body after treatment called measurable residual disease (MRD).

Each cell in the body has chromosomes that carry genes. Genes give instructions that tell each cell what to do. Karyotyping uses a microscope to look for abnormal changes in the chromosomes of leukemia cells. The results of this test help your doctor identify your ALL subtype and plan your treatment.

This test is used to look at the genes or chromosomes in cells and tissues. Doctors use this test to find changes in chromosomes and genes in the leukemia cells. 

This test finds and measures some genetic mutations and chromosome changes that are too small to be seen, even with a microscope. PCR is also used to test for MRD. 

This test looks for mutations in the genes of ALL cells. Certain mutations are markers that can help doctors identify a patient’s ALL subtype and predict how the disease will progress. Next-generation sequencing is also used to test for MRD.  

Leukemia cells can travel to the central nervous system (CNS). The CNS includes the brain and the spinal cord. A lumbar puncture, also called a spinal tap, is a procedure to collect cerebrospinal fluid, the fluid that flows around the brain and spinal cord. It is done to find out if there are leukemia cells in your CNS.

A thin needle is inserted between two vertebrae (bones that form the spinal column) and into the cerebrospinal fluid. A sample of the fluid is removed and examined under a microscope to look for leukemia cells.

A lumbar puncture is also used to inject chemotherapy drugs to the CNS. This is called intrathecal chemotherapy. Intrathecal chemotherapy is one type of CNS-directed therapy. All treatment plans for ALL include treatment for CNS-directed therapy to prevent the spread of ALL to the CNS.

Diagnosing ALL 

After your doctor takes samples of your blood and bone marrow, a hematopathologist confirms a diagnosis and identifies the ALL subtype. A hematopathologist is a specialist who studies blood cell diseases by looking at samples of blood and marrow cells and other tissues. 

The diagnosis of ALL is confirmed by identifying leukemic blasts of lymphoid origin (lymphoblasts) in the bone marrow samples; and determining the percentage of blast cells in the bone marrow.  

Typically, there are no blast cells in the blood and no more than 5 percent of the cells in the bone marrow are blast cells. In ALL, at least 20 percent of the cells in the bone marrow are lymphoblasts.  

If you're diagnosed with ALL, blood and bone marrow tests are also administered during or after treatment to see how the ALL cells are responding to therapy.

Newly diagnosed checklist 

This infographic from the College of American Pathologists (CAP) and the American Society of Hematology (ASH) provides practical guidance for patients and caregivers coping with a new diagnosis of an acute leukemia. It will help ensure that you receive the best treatment for your unique situation. 

Diagnosing ALL subtypes  

Doctors classify ALL into subtypes by using various tests. It's important to get an accurate diagnosis since your subtype plays a large part in deciding the type of treatment you'll receive.  

Depending on your ALL subtype, the doctor will determine: 

  • The type of drug combination needed for your treatment
  • The length of time you'll need to be in treatment
  • Other types of treatment that may be needed to achieve the best outcomes 

There are many subtypes of ALL, each caused by different genetic abnormalities (gene or chromosome changes) in the leukemia cells. It is important to know your ALL subtype because it affects both your prognosis (outlook) and your treatment plan.

The World Health Organization (WHO) divides ALL into different subtypes. For a list of the WHO classification system of ALL subtypes, see our booklet Acute lymphoblastic leukemia in adults: In detail. 

If you are not sure of your ALL subtype, ask your doctor what it is and to explain how your ALL subtype affects your treatment.

Genetic changes 

In addition to classifying ALL as either B-cell or T-cell, it is further classified based on certain changes to the chromosomes and genes found in the leukemia cells. This identification of specific genetic abnormalities is critical for disease evaluation, risk stratification, and treatment planning. 

Translocations are the most common type of genetic change associated with ALL. In a translocation, the DNA from one chromosome breaks off and becomes attached to a different chromosome. Sometimes pieces from two different chromosomes trade places. A translocation may result in a “fusion gene,” an abnormal gene that is formed when two different genes are fused together. 

Another type of genetic change that occurs in ALL is the result of numerical abnormalities. A numerical abnormality is either a gain or loss in the number of chromosomes from the normal 46 chromosomes. A change in the number of chromosomes can affect the growth, development, and functioning of body systems.

About 75 percent of adult ALL cases can be classified into subgroups based on chromosomal abnormalities and genetic mutations. Not all patients have the same genetic changes. Some changes are more common than others, and some have a greater effect on a patient’s prognosis. 

Get free, one-on-one support

Call, email, or chat with a member of our highly trained support team.

Blood Cancer United resources

Find free, specialized guidance and information for every type of blood cancer, request financial support, find emotional support, and connect with other members of the blood cancer community.

We are Blood Cancer United.

Everyone affected by blood cancer—patients, survivors, caregivers, researchers, advocates, fundraisers, everyone—has a story. Share yours.
five-year-old leukemia survivor, Vera Padilla of Sacramento, CA

Monica

Family member, caregiver, advocate

Nevaeh age 2 standing outside in a lacy white summer dress, cowbow boots and hat, and a huge smile

Nevaeh

acute myeloid leukemia (AML+MLLr)

Portrait of a child standing in a grassy field surrounded by wildflowers and greenery, wearing a navy button-down shirt. The image represents hope, resilience, and childhood blood cancer awareness, highlighting the experiences of young blood cancer patients, survivors, and families while emphasizing the importance of research, support, and community.

Henry

B-cell acute lymphoblastic leukemia (B-ALL)

Jarvis, Pre B acute lymphoblastic leukemia (ALL) patient

Jarvis

Pre-B acute lymphoblastic leukemia (ALL)

Savanna and Asher, pediatric blood cancer patient, holding a sign "Asher is a perfect match"

Savanna

pre-B-cell acute lymphoblastic leukemia (pre-B-ALL)

Rachel, pediatric blood cancer as an adult at the same stem cell transplant unti they were treated

Rachel

acute lymphoblastic leukemia (ALL)

Two men with arms around each others shoulders

Kabir

acute lymphoblastic leukemia (ALL)

Headshot of Isabelle - a young woman with blond hair and blue eyes

Isabelle

Acute lymphoblastic leukemia (ALL)

A young child stands indoors on a hardwood floor wearing a lavender dress, colorful socks, and a pink head wrap. The portrait highlights a moment of confidence and individuality during a blood cancer experience, capturing the resilience of children and families navigating treatment, recovery, and survivorship. This image reflects hope, strength, and everyday life affected by pediatric blood cancer.

Kelly

Family member and caregiver

Two people wearing bright yellow banana costumes pose outdoors near an active volcanic eruption, with lava and a large plume of smoke rising in the background. The playful travel photo captures a memorable moment of adventure, humor, and connection. The image accompanies a blood cancer survivor story, reflecting resilience, celebrating life after a blood cancer diagnosis, and finding joy in meaningful experiences.

Thomas

acute lymphoblastic leukemia (ALL)

Portrait of a blood cancer advocate standing in front of a red Leukemia & Lymphoma Society event backdrop, wearing a wide-brimmed hat, glasses, and a patterned top. The image highlights community engagement, blood cancer awareness, and support for patients, survivors, and families affected by leukemia, lymphoma, myeloma, and other blood cancers. Featured as part of a blood cancer survivor story, the photo reflects advocacy, resilience, and the impact of collective action in the blood cancer community.

Angie

Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

Portrait of a blood cancer advocate standing in front of a green floral background featuring a white dove graphic. The individual wears glasses and a sleeveless top while posing for the camera. Featured as part of a blood cancer survivor story, the image highlights awareness, remembrance, resilience, and community support for people affected by leukemia, lymphoma, myeloma, and other blood cancers. The photo reflects hope and the lasting impact of blood cancer advocacy and patient storytelling.

Joan

Family member and supporter

The Leukemia & Lymphoma Society (LLS) is now Blood Cancer United. Learn more.